NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $4.55 +0.03 (+0.66%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$4.48▼$4.8450-Day Range$4.05▼$6.8052-Week Range$1.06▼$11.88Volume1.01 million shsAverage Volume2.14 million shsMarket Capitalization$313.09 millionP/E RatioN/ADividend YieldN/APrice Target$10.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get C4 Therapeutics alerts: Email Address C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside122.5% Upside$10.13 Price TargetShort InterestBearish21.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector847th out of 896 stocksBiological Products, Except Diagnostic Industry144th out of 152 stocks 3.2 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.13% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 2.6 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsMassive July 4th Discount InsideTo celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.Claim your exclusive offer here>>> About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesJuly 4 at 3:01 AM | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Increase in Short InterestJuly 1, 2024 | americanbankingnews.comAnalysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $10.13July 5, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.July 1, 2024 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) & Scilex (NASDAQ:SCLX) Head-To-Head SurveyJune 10, 2024 | globenewswire.comC4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsMay 22, 2024 | finance.yahoo.comWe Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business GrowthMay 17, 2024 | finance.yahoo.comC4 Therapeutics, Inc. (CCCC)May 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)July 5, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.May 10, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic CollaborationsMay 9, 2024 | markets.businessinsider.comC4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable FinancialsMay 9, 2024 | markets.businessinsider.comKey Takeaways From C4 Therapeutics Analyst RatingsMay 8, 2024 | investorplace.comCCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | seekingalpha.comArvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationApril 9, 2024 | globenewswire.comC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumApril 8, 2024 | msn.comC4 Dips on Release of DataApril 8, 2024 | finance.yahoo.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024April 8, 2024 | globenewswire.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024March 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callMarch 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsSee More Headlines Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/05/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$10.13 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+122.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-629.24% Pretax Margin-622.85% Return on Equity-52.85% Return on Assets-34.01% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.08 Sales & Book Value Annual Sales$20.76 million Price / Sales15.08 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.12Miscellaneous Outstanding Shares68,810,000Free Float63,322,000Market Cap$313.09 million OptionableOptionable Beta3.07 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsInhibrxNASDAQ:INBXCompugenNASDAQ:CGENNurix TherapeuticsNASDAQ:NRIXVir BiotechnologyNASDAQ:VIRSana BiotechnologyNASDAQ:SANAView All CompetitorsInstitutional OwnershipLynx1 Capital Management LPBought 500,266 shares on 5/30/2024Ownership: 5.282%Farallon Capital Management LLCBought 28,000 shares on 5/24/2024Ownership: 0.041%Walleye Trading LLCBought 2,200 shares on 5/17/2024Ownership: 0.000%Bain Capital Life Sciences Investors LLCSold 500,000 shares on 5/16/2024Ownership: 1.660%Caxton Associates LPBought 21,002 shares on 5/16/2024Ownership: 0.031%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price target for 2024? 7 equities research analysts have issued 1 year target prices for C4 Therapeutics' stock. Their CCCC share price targets range from $2.00 to $20.00. On average, they predict the company's stock price to reach $10.13 in the next year. This suggests a possible upside of 122.5% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2024? C4 Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, CCCC shares have decreased by 19.5% and is now trading at $4.55. View the best growth stocks for 2024 here. Are investors shorting C4 Therapeutics? C4 Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 14,540,000 shares, an increase of 9.7% from the May 31st total of 13,260,000 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 10.2 days. View C4 Therapeutics' Short Interest. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its earnings results on Wednesday, May, 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $10.93 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 52.85% and a negative net margin of 629.24%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.